Archives — July 2017 back to current month (7)

Canadian Medical Cannabis Provider Expanding into US Market Through RTO (07/25/2017)

A company with Canadian medical cannabis provider Aphria's backing is doing a reverse takeover on the Canadian Securities Exchange and expects to begin trading on July 26.

more>

DNA-Based Compound Shuts Down Seasonal Flu in Preclinical Study (07/19/2017)

A U.S. biotech developing vaccines to fight a number of infectious diseases has generated promising preclinical results with a platform therapy targeting influenza, and expects to enter the clinic with a similar platform compound targeting Ebola in 2018.

more>

Progress in Pain Control and Liver Disease Programs Spurs Rise in Company's Rating (07/19/2017)

News about progress in two of this biotech's development programs prompted a rating upgrade by analyst Adam Walsh of Stifel Nicolaus & Company.

more>

Biotech with Alzheimer's Focus Makes Progress on Several Fronts (07/18/2017)

In its corporate update for Q2/17, a Canada-based biotech targeting neurological disorders including Alzheimer's disease informed investors of advancements in several programs, including designation of a second validated lead compound in development.

more>

2017 Small-Cap Biotech Watchlist Update: Up 21% at the End of Q2/17 (07/13/2017)

If an investor had purchased an equal dollar amount of each company on The Life Sciences Report's 2017 Small-Cap Biotech Watchlist at the beginning of the year, that portfolio would show a gain of about 21% as of July. This is primarily due to the performance of a handful of companies that have been moving their assets farther down the development pipeline, according to the analysts who follow them.

more>

Multifaceted Biotech Company Poised to Begin Trading on Canadian Securities Exchange (07/11/2017)

A Vancouver-based biotech firm that aims to become the first preventative medicine company is expected to commence trading on the Canadian Securities Exchange July 14.

more>

Analysts Take Note as Small-Cap Biotech Completes Early Enrollment for Phase 3 Trial (07/05/2017)

With enrollment complete in its Phase 3 trial of a compound that treats post-operative pain, and an infusion of cash from a new partnership with a major pharmaceutical corporation, one analyst has initiated coverage of this California-based company, and another has reiterated his investment thesis.

more>

More Archives

2017Nov Oct Sep Aug Jul Jun May Apr Mar Feb Jan

2016Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2015Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2014Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2013Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2012Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports Life Sciences Report Newsletter Free

A valid email address is required to subscribe

Notable Quotes

"We are initiating coverage on RVX with a Buy rating."
– David Kideckel, Beacon Securities Ltd.
"RXII's sd-rxRNA can augment already amazing results in immunotherapy."
– John Vandermosten, Zacks Small-Cap Research